A Medical Device Daily

CryoCath Technologies (Montreal), a developer of cryotherapy systems to treat cardiovascular disease, yesterday reported that Steven Arless has resigned, as president/CEO and as a company director, to pursue other interests.

Henri Vienneau, company chairman, will serve as interim president/CEO, and CryoCath said it is conducting a search for a permanent replacement.

“CryoCath has accomplished a lot since its inception, and we are grateful to Steve for his years of dedicated service to the company; we wish him well,” said Vienneau. “CryoCath continues to pursue many opportunities, and we are enthusiastic about the company's prospects going forward.”

Vienneau served as president and general manager of the Canadian division of Mallinckrodt Medical for more than 15 years, his other positions including responsibility for chemical and medical sales, marketing and manufacturing in Canada as well as in certain international markets. Other experience includes serving on the board and acting as chairman from 1989-1995 of the association of Medical Device Companies of Canada, and providing consulting services to medical device and biotech firms.

CryoCath has multiple products approved in the U.S., across Europe and several other countries.